Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.

Clinical and translational science - 1 Sept 2020

Fohner Alison E, Rettie Allan E, Thai Khanh K, Ranatunga Dilrini K, Lawson Brian L, Liu Vincent X, Schaefer Catherine A

Abstract excerpt

The role of cytochrome P450 (CYP)2C9 and CYP2C19 genetic variation in risk for phenytoin-induced cutaneous adverse drug events is not well understood independently of the human leukocyte antigen B (HLA-B)*15:02 risk allele. In the multi-ethnic resource for Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort, we identified 382 participants who filled a phenytoin prescription between 2005 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Eruptions

Share to HLA-B15 Antigen

Share to Molecular Epidemiology

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Phenytoin

Source

Open in PubMed Open full text

Identifiers

PMID: 32216088
DOI: 10.1111/cts.12787
PMCID: PMC7485959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.PMID 32216088Read ↗

An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effectsSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.Semantic proximity Read ↗

Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.Semantic proximity Read ↗

CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Semantic proximity Read ↗

Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population.Semantic proximity Read ↗

HLA Alleles and CYP 2C9*3 as Predictors of Phenytoin Hypersensitivity in East AsiansSemantic proximity Read ↗

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatmentSemantic proximity Read ↗

Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in PeruSemantic proximity Read ↗

HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugsSemantic proximity Read ↗

Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.